MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Level of glial neurotrophic factor in the blood plasma depending on the duration of Parkinson’s disease

B. Muminov, R. Matmurodov, E. Abduqodirov (Tashkent, Uzbekistan)

Meeting: 2022 International Congress

Abstract Number: 1346

Keywords: Dopaminergic neurons, Microglia, Parkinson’s

Category: Parkinson's Disease: Molecular Mechanisms of Disease

Objective: To study the level of glial neurotrophic factor in the blood plasma depending on the duration of PD.

Background: Study of the biochemical aspects of Parkinson’s disease (PD) is an actual problem of modern neurology

Method: The material of this study was 78 patients with of PD. Duration of the disease – is 0.5 to 7 years. The control group consisted of 10 patients without symptoms of PD; Determines the content of glial neurotrophic factor in the blood serum by enzyme immunoassay performed with specific test systems developed on the basis of appropriate monoclonal antibodies on the analyzer Hospitex Diagnostics, Italy according to the instructions supplied with the kit.

Results: The results show that if the duration of 6-7 year, the level of glial neurotrophic factor in the blood plasma was 25,12 pg/ml, if the duration of 4-5 year, the level of glial neurotrophic factor was 32,65 pg/ml and in the duration 2-4 years the level of glial neurotrophic factor was 45,35 pg/ml, and in the control group the level of protein in blood plasma was 73.558±8.2 pg/ml. The level of glial neurotrophic factor in the blood plasma of PD is dependent on the degree of neurodegeneration. Patients with Parkinson’s disease have a relatively high level of glial neurotrophic factor in the serum in the early stages of the disease

Conclusion: The level of glial neurotrophic factor in the blood plasma of PD does not only depend on the clinical manifestations, and also depends on the duration of the disease.

To cite this abstract in AMA style:

B. Muminov, R. Matmurodov, E. Abduqodirov. Level of glial neurotrophic factor in the blood plasma depending on the duration of Parkinson’s disease [abstract]. Mov Disord. 2022; 37 (suppl 2). https://www.mdsabstracts.org/abstract/level-of-glial-neurotrophic-factor-in-the-blood-plasma-depending-on-the-duration-of-parkinsons-disease/. Accessed June 15, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2022 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/level-of-glial-neurotrophic-factor-in-the-blood-plasma-depending-on-the-duration-of-parkinsons-disease/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley